[Form 4] ALX Oncology Holdings Inc. Insider Trading Activity

Rhea-AI Filing Summary

ALX Oncology Holdings, Inc. (ALXO) director and Chief Executive Officer Jason Lettmann reported a small sale of Common Stock on 08/15/2025 to satisfy tax obligations from RSU vesting. The filing shows 2,382 shares sold at a weighted-average price of $0.6404 (sales occurred between $0.64 and $0.66). After the reported disposition, the reporting person beneficially owns 212,888 shares, which includes 3,000 shares acquired under the companys employee stock purchase plan on 06/30/2025. The Form 4 was signed by power of attorney on 08/19/2025.

Insights

Financial Analyst

TL;DR Insider sold a small number of shares to cover taxes; remaining stake remains sizeable.

Jason Lettmanns sale of 2,382 shares is disclosed as tax-withholding related following RSU vesting, with sale prices between $0.64 and $0.66 and a weighted-average of $0.6404. The post-transaction beneficial ownership of 212,888 shares indicates continued meaningful alignment with shareholders. The transaction appears administrative rather than a signal of changed confidence, based solely on the filings explicit statements.

Corporate Governance Expert

TL;DR Routine tax-related disposition by an insider; governance disclosure is complete and appropriately annotated.

The Form 4 documents the nature of the disposition (tax withholding on vested RSUs) and provides the weighted-average sale price range and aggregation details including recent ESPP participation. The filing includes a power-of-attorney signature and the explanatory footnotes required for clarity, meeting standard disclosure expectations for insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lettmann Jason

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		S(1)		2,382	D	$0.6404(2)	212,888(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2025.

	/s/ Shelly Pinto, by power of attorney	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ALXO insider Jason Lettmann report on Form 4?

The filing reports a sale of 2,382 shares on 08/15/2025 at a weighted-average price of $0.6404, and beneficial ownership of 212,888 shares following the transaction.

Why were the ALXO shares sold by the insider?

The sale was made to satisfy tax obligations arising from the vesting of restricted stock units, as stated in the filing.

Does the Form 4 show any derivative transactions for ALXO by the reporting person?

No. Table II for derivative securities contains no entries in this filing; only non-derivative common stock transactions are reported.

Did the insider acquire any ALXO shares recently?

Yes. The filing notes 3,000 shares were acquired under the issuers employee stock purchase plan on 06/30/2025.

When was the Form 4 signed and by whom?

The Form 4 was signed by /s/ Shelly Pinto, by power of attorney on 08/19/2025, as indicated in the filing.